Drug Safety

, Volume 31, Issue 7, pp 557–560

Perioperative Safety of Aprotinin in Coronary Artery Bypass Graft Surgery

Is there Life After BART?


  1. 1.
    Mangano DT, Tudor JC, Dietzel C. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation: the risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353–65PubMedCrossRefGoogle Scholar
  2. 2.
    Augoustides J. Con: aprotinin should not be used in cardiac surgery with cardiopulmonary bypass. J Cardiothor Vasc Anesth 2007; 21: 302–4CrossRefGoogle Scholar
  3. 3.
    Brown JR, Birkmeyer NJO, O’Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801–13PubMedCrossRefGoogle Scholar
  4. 4.
    Henry DA, Carless PA, Moxey AJ, et al. Antifibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007; 4: CD001886Google Scholar
  5. 5.
    Fergusson D, Glass KC, Hutton B, et al. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005; 2: 218–30PubMedCrossRefGoogle Scholar
  6. 6.
    Augoustides JG, Fleisher LA. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005; 2: 231–2Google Scholar
  7. 7.
    Bayer HealthCare Pharmaceuticals. Important trasylol safety information. November 5, 2007 [online]. Available from URL: http://www.trasylol.com [Accessed 2008May 27]
  8. 8.
    Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319–31PubMedCrossRefGoogle Scholar
  9. 9.
    Ray WA, Stein CM. The aprotinin story: is BART the final chapter? N Engl J Med 2008; 358: 2398–400PubMedCrossRefGoogle Scholar
  10. 10.
    Kluth M, Lueth JU, Zittermann A, et al. Low-dose aprotinin use is not associated with adverse effects on safety variables in coronary artery bypass graft surgery. Drug Saf 2008; 31(7): 617–26PubMedCrossRefGoogle Scholar
  11. 11.
    Strouch ZY, Chaney MA, Augoustides JG, et al. Case 1–2008: one institution’s decreasing use of aprotinin during cardiac surgery in 2006. J Cardiothorac Vasc Anesth 2008; 22: 139–46PubMedCrossRefGoogle Scholar
  12. 12.
    Kincaid EH, Ashburn DA, Hoyle JR, et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg 2005; 80: 1388–93PubMedCrossRefGoogle Scholar
  13. 13.
    Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358: 784–93PubMedCrossRefGoogle Scholar
  14. 14.
    Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358: 771–83PubMedCrossRefGoogle Scholar
  15. 15.
    Pagano G, Howell NJ, Freemantle N, et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 2008; 135: 495–502PubMedCrossRefGoogle Scholar
  16. 16.
    US Food and Drug Administration. FDA clinical advisory on aprotinin [online]. Available from URL: http://www.fda.gov/cder/infopage/aprotinin/defaulthtm [Accessed 2008 May 27]
  17. 17.
    Dietrich W, Busley R, Kriner M. High-dose aprotinin in cardiac surgery: is high-dose enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg 2006; 103: 1074–81PubMedCrossRefGoogle Scholar
  18. 18.
    Ferguson TB. Aprotinin: are there lessons learned. JAMA 297: 527–529Google Scholar
  19. 19.
    Ray WA. Learning from aprotinin-mandatory trials of compar-ative efficacy and safety needed. N Engl J Med 2008; 358: 840–2PubMedCrossRefGoogle Scholar
  20. 20.
    Sundt TM. The demise of aprotinin: our share of the blame. J Thorac Cardiovasc Surg 2008; 135: 729–31PubMedCrossRefGoogle Scholar
  21. 21.
    Apostolakis E, Panagopoulos H, Koletsis EN, et al. Influence of ultra-low dose aprotinin on thoracic surgical procedures: a prospective randomized trial. J Cardiothorac Surg 2008 Mar 24; 3: 14PubMedCrossRefGoogle Scholar
  22. 22.
    Shuhaiber JH, Goldsmith K, Large SR, et al. Does perioperative use of aprotinin reduce the rejection rate in heart transplant recipients? Eur J Cardiothorac Surg 2008; 33(5): 849–55PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Cardiothoracic and Vascular Section, Anesthesiology and Critical CareHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations